Cargando…

Radiotherapy for nonagenarians: the value of biological versus chronological age

BACKGROUND: The number of nonagenarian cancer patients (≥ 90 years) is continuously increasing, and radiotherapy is performed in a relevant proportion of patients, as surgery and chemotherapy are often not feasible for these patients. However, the evidence regarding the feasibility and treatment out...

Descripción completa

Detalles Bibliográficos
Autores principales: Sprave, Tanja, Rühle, Alexander, Stoian, Raluca, Weber, Alina, Zamboglou, Constantinos, Nieder, Carsten, Grosu, Anca-Ligia, Nicolay, Nils H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236131/
https://www.ncbi.nlm.nih.gov/pubmed/32430009
http://dx.doi.org/10.1186/s13014-020-01563-x
_version_ 1783536099165995008
author Sprave, Tanja
Rühle, Alexander
Stoian, Raluca
Weber, Alina
Zamboglou, Constantinos
Nieder, Carsten
Grosu, Anca-Ligia
Nicolay, Nils H.
author_facet Sprave, Tanja
Rühle, Alexander
Stoian, Raluca
Weber, Alina
Zamboglou, Constantinos
Nieder, Carsten
Grosu, Anca-Ligia
Nicolay, Nils H.
author_sort Sprave, Tanja
collection PubMed
description BACKGROUND: The number of nonagenarian cancer patients (≥ 90 years) is continuously increasing, and radiotherapy is performed in a relevant proportion of patients, as surgery and chemotherapy are often not feasible for these patients. However, the evidence regarding the feasibility and treatment outcomes after radiotherapy for this patient group is very limited. METHODS: All nonagenarian patients receiving (chemo) radiotherapy between 2009 and 2019 at the University of Freiburg - Medical Center were analyzed for patterns of care, overall survival (OS) and therapy-associated toxicities according to the Common Terminology Criteria for Adverse Events. Uni- and multivariate Cox regression analyses were conducted to assess the influence of patient- and treatment-related factors on patient outcomes. RESULTS: One hundred nineteen patients with a total of 137 irradiated lesions were included in this analysis. After a median follow-up of 27 months, median OS was 10 months with a 3-year OS amounting to 11.1%. Univariate analyses demonstrated that a reduced performance status (HR = 1.56, 95% CI 1.00–2.45, p < 0.05), a higher burden of comorbidities (HR = 2.00, 95% CI 1.00–4.10, p < 0.05) and higher UICC tumor stages (HR = 2.21, 95% CI 1.14–4.26, p < 0.05) were associated with impaired survival rates. Split-course treatments (HR = 2.05, 95% CI 1.07–3.94, p < 0.05), non-completion of radiotherapy (HR = 7.17, 95% CI 3.88–13.26, p < 0.001) and palliative treatments (HR = 2.84, 95% CI 1.68–4.81, p < 0.05) were found to result in significantly reduced OS. In the multivariate analysis, split-course concepts (HR = 2.21, 95% CI 1.10–4.37, p < 0.05) and palliative treatments (HR = 3.19, 95% CI 1.77–5.75, p < 0.001) significantly deteriorated outcomes, while impaired ECOG status (HR = 1.49, 95% CI 0.91–2.43, p = 0.11) did not. The vast majority of patients reported either no (n = 40; 33.6%) or grade 1–2 acute toxicities (n = 66; 55.5%), and only very few higher-grade toxicities were observed in our study. CONCLUSION: Radiotherapy for nonagenarian patients is generally feasible and associated with a low toxicity profile. Given the relatively poor OS rates and the importance of the quality of life for this patient group, individualized treatment regimens including hypofractionation concepts should be considered.
format Online
Article
Text
id pubmed-7236131
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72361312020-05-27 Radiotherapy for nonagenarians: the value of biological versus chronological age Sprave, Tanja Rühle, Alexander Stoian, Raluca Weber, Alina Zamboglou, Constantinos Nieder, Carsten Grosu, Anca-Ligia Nicolay, Nils H. Radiat Oncol Research BACKGROUND: The number of nonagenarian cancer patients (≥ 90 years) is continuously increasing, and radiotherapy is performed in a relevant proportion of patients, as surgery and chemotherapy are often not feasible for these patients. However, the evidence regarding the feasibility and treatment outcomes after radiotherapy for this patient group is very limited. METHODS: All nonagenarian patients receiving (chemo) radiotherapy between 2009 and 2019 at the University of Freiburg - Medical Center were analyzed for patterns of care, overall survival (OS) and therapy-associated toxicities according to the Common Terminology Criteria for Adverse Events. Uni- and multivariate Cox regression analyses were conducted to assess the influence of patient- and treatment-related factors on patient outcomes. RESULTS: One hundred nineteen patients with a total of 137 irradiated lesions were included in this analysis. After a median follow-up of 27 months, median OS was 10 months with a 3-year OS amounting to 11.1%. Univariate analyses demonstrated that a reduced performance status (HR = 1.56, 95% CI 1.00–2.45, p < 0.05), a higher burden of comorbidities (HR = 2.00, 95% CI 1.00–4.10, p < 0.05) and higher UICC tumor stages (HR = 2.21, 95% CI 1.14–4.26, p < 0.05) were associated with impaired survival rates. Split-course treatments (HR = 2.05, 95% CI 1.07–3.94, p < 0.05), non-completion of radiotherapy (HR = 7.17, 95% CI 3.88–13.26, p < 0.001) and palliative treatments (HR = 2.84, 95% CI 1.68–4.81, p < 0.05) were found to result in significantly reduced OS. In the multivariate analysis, split-course concepts (HR = 2.21, 95% CI 1.10–4.37, p < 0.05) and palliative treatments (HR = 3.19, 95% CI 1.77–5.75, p < 0.001) significantly deteriorated outcomes, while impaired ECOG status (HR = 1.49, 95% CI 0.91–2.43, p = 0.11) did not. The vast majority of patients reported either no (n = 40; 33.6%) or grade 1–2 acute toxicities (n = 66; 55.5%), and only very few higher-grade toxicities were observed in our study. CONCLUSION: Radiotherapy for nonagenarian patients is generally feasible and associated with a low toxicity profile. Given the relatively poor OS rates and the importance of the quality of life for this patient group, individualized treatment regimens including hypofractionation concepts should be considered. BioMed Central 2020-05-19 /pmc/articles/PMC7236131/ /pubmed/32430009 http://dx.doi.org/10.1186/s13014-020-01563-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sprave, Tanja
Rühle, Alexander
Stoian, Raluca
Weber, Alina
Zamboglou, Constantinos
Nieder, Carsten
Grosu, Anca-Ligia
Nicolay, Nils H.
Radiotherapy for nonagenarians: the value of biological versus chronological age
title Radiotherapy for nonagenarians: the value of biological versus chronological age
title_full Radiotherapy for nonagenarians: the value of biological versus chronological age
title_fullStr Radiotherapy for nonagenarians: the value of biological versus chronological age
title_full_unstemmed Radiotherapy for nonagenarians: the value of biological versus chronological age
title_short Radiotherapy for nonagenarians: the value of biological versus chronological age
title_sort radiotherapy for nonagenarians: the value of biological versus chronological age
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236131/
https://www.ncbi.nlm.nih.gov/pubmed/32430009
http://dx.doi.org/10.1186/s13014-020-01563-x
work_keys_str_mv AT spravetanja radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT ruhlealexander radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT stoianraluca radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT weberalina radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT zamboglouconstantinos radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT niedercarsten radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT grosuancaligia radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage
AT nicolaynilsh radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage